Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (NEXT-CAT)
Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous thromboembolism (CAT). A total of 2,300 patients with active cancer and objectively confirmed venous thromboembolism will be randomized in a 1:1 ratio to receive edoxaban-based or apixaban-based treatment. The primary objective is to determine whether edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to net adverse clinical events (NACE), defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality in patients with active cancer. Patients with CAT are at increased risk of both recurrent venous thromboembolism and bleeding during anticoagulant treatment, making the balance between efficacy and safety particularly important when selecting an anticoagulant.
Non-vitamin K antagonist oral anticoagulants have become established treatment options for CAT. Edoxaban and apixaban are both factor Xa inhibitors with demonstrated efficacy and safety in patients with CAT. However, they have been evaluated separately against low-molecular-weight heparin, and direct randomized comparisons between edoxaban and apixaban are lacking. The two agents also differ in dosing frequency, dose-reduction strategies, pharmacokinetic characteristics, and renal elimination. Whether these differences translate into differences in overall clinical outcomes in patients with CAT remains uncertain.
NEXT-CAT is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to directly compare edoxaban-based treatment with apixaban-based treatment in patients with active cancer and objectively confirmed venous thromboembolism. A total of 2,300 participants will be randomized in a 1:1 ratio, with randomization stratified by participating center and the presence of gastrointestinal cancer at baseline.
The primary hypothesis is that edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to the incidence of net adverse clinical events (NACE). The primary endpoint is a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Participants will be followed at 1, 3, 6, 9, 12, and 18 months after randomization and annually thereafter, with follow-up continuing until 1 year after enrollment of the last participant.
Clinical events corresponding to the primary and secondary endpoints will be evaluated by an independent Clinical Event Adjudication Committee blinded to treatment allocation.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Yunjeong Song, RN
- Número de teléfono: 82-2-3410-2171
- Correo electrónico: yjung.song@sbri.co.kr
Ubicaciones de estudio
-
-
-
Busan, Corea del Sur
- Dong-A University Hospital
-
Contacto:
- Sung-Hyun Kim
-
Investigador principal:
- Sung-Hyun Kim, MD, PhD
-
Goyang, Corea del Sur
- Inje University Ilsan Paik Hospital
-
Contacto:
- Min Sun Kim
-
Investigador principal:
- Min Sun Kim
-
Gwangmyeong, Corea del Sur
- Chung-Ang University Gwangmyeong Hospital
-
Contacto:
- Eun Jeong Cho
-
Investigador principal:
- Eun Jeong Cho
-
Hwasun, Corea del Sur
- Chonnam National University Hwasun Hospital
-
Contacto:
- Hyukjin Park
-
Investigador principal:
- Hyukjin Park
-
Jeonju, Corea del Sur
- Chonbuk National University Hospital
-
Contacto:
- Ho-Young Yhim
-
Investigador principal:
- Ho-Young Yhim, MD, PhD
-
Seoul, Corea del Sur
- Kangbuk Samsung Hospital
-
Contacto:
- Jiwon Kim
-
Investigador principal:
- Jiwon Kim
-
Seoul, Corea del Sur
- Korea University Anam Hospital
-
Contacto:
- So Ree Kim
-
Investigador principal:
- So Ree Kim
-
Seoul, Corea del Sur
- Samsung Medical Center
-
Sub-Investigador:
- Se-Hoon Lee, MD, PhD
-
Sub-Investigador:
- Taek Kyu Park, MD, PhD
-
Contacto:
- Yunjeong Song, RN
- Correo electrónico: yjung.song@sbri.co.kr
-
Investigador principal:
- Eun Kyoung Kim, MD, PhD
-
Sub-Investigador:
- David Hong, MD, PhD
-
Seoul, Corea del Sur
- Seoul National University Hospital
-
Contacto:
- Sang-Hoon Na, MD, PhD
-
Investigador principal:
- Sang-Hoon Na, MD, PhD
-
Seoul, Corea del Sur
- Konkuk University Medical Center
-
Contacto:
- Ji-Won Hwang
-
Investigador principal:
- Ji-Won Hwang
-
Seoul, Corea del Sur
- Seoul St. Mary's Hospital
-
Contacto:
- Mi-Hyang Jung
-
Investigador principal:
- Mi-Hyang Jung, MD, PhD
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Corea del Sur
- National Cancer Center
-
Contacto:
- Mi-Hyang Kwak
-
Investigador principal:
- Mi-Hyang Kwak
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age ≥19 years.
-
Objectively confirmed symptomatic or incidentally detected venous thromboembolism (VTE), including:
- Proximal deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Both DVT and PE.
-
Any type of active cancer, defined by at least one of the following:
- Cancer diagnosed within the previous 6 months
- Locally advanced or metastatic cancer
- Receipt of cancer-directed therapy (chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy, or cancer surgery) within the previous 6 months
- Cancer not in complete remission at the time of enrollment
- Ongoing cancer treatment or residual cancer.
-
Ability to understand the risks, benefits, and treatment alternatives of the study and to voluntarily provide written informed consent.
Exclusion Criteria:
- Known hypersensitivity or contraindication to either study drug (edoxaban or apixaban).
- Severe renal impairment (creatinine clearance <15 mL/min) or dialysis.
- Active major bleeding.
- An indication requiring alternative anticoagulation, such as a mechanical heart valve or moderate-to-severe mitral stenosis.
- Antiphospholipid syndrome.
- Life expectancy <6 months due to cancer progression or comorbid conditions, or anticipated poor treatment adherence, as determined by the investigator.
- Pregnancy or breastfeeding.
- Moderate or severe hepatic impairment classified as Child-Pugh class B or C.
- Thrombocytopenia with a platelet count <50,000/mm³.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Edoxaban-based Treatment
Participants randomized to this arm will receive oral edoxaban once daily. The standard dose is 60 mg once daily, with dose reduction according to the protocol based on renal function, body weight, concomitant P-glycoprotein inhibitors, and other prespecified clinical factors. |
Edoxaban is administered orally once daily. The standard dose is 60 mg once daily. The dose is reduced to 30 mg once daily in participants with a creatinine clearance of 15-50 mL/min, body weight ≤60 kg, or concomitant use of specified P-glycoprotein inhibitors. In participants aged ≥80 years who are considered at high risk of bleeding and meet the prespecified criteria, further dose reduction to 15 mg once daily may be considered. |
|
Comparador activo: Apixaban-based Treatment
Participants randomized to this arm will receive oral apixaban twice daily. The standard dose is 5 mg twice daily, with dose reduction to 2.5 mg twice daily according to the prespecified dose-reduction criteria in the protocol. |
Apixaban is administered orally at a standard dose of 5 mg twice daily. The dose is reduced to 2.5 mg twice daily in participants who meet the prespecified dose-reduction criteria, including those who meet at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, or those with severe renal impairment with a creatinine clearance of 15-29 mL/min. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Net Adverse Clinical Events (NACE)
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of a net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. |
From randomization until 1 year after enrollment of the last participant
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recurrent Venous Thromboembolism or Venous Thromboembolism-related Death
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of recurrent venous thromboembolism or venous thromboembolism-related death. |
From randomization until 1 year after enrollment of the last participant
|
|
Recurrent Venous Thromboembolism
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of objectively confirmed recurrent venous thromboembolism, including recurrent deep vein thrombosis or recurrent pulmonary embolism. |
From randomization until 1 year after enrollment of the last participant
|
|
Venous Thromboembolism-related Death
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Death resulting from objectively confirmed fatal pulmonary embolism, recurrent venous thromboembolism directly leading to death, or unexplained death for which no alternative cause is identified and which is adjudicated as venous thromboembolism-related by the Clinical Event Adjudication Committee. |
From randomization until 1 year after enrollment of the last participant
|
|
Major Bleeding According to International Society on Thrombosis and Haemostasis Criteria
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of major bleeding according to International Society on Thrombosis and Haemostasis criteria, including fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a decrease in hemoglobin of at least 2 g/dL, or bleeding requiring transfusion of at least 2 units of whole blood or packed red blood cells. |
From randomization until 1 year after enrollment of the last participant
|
|
Clinically Relevant Non-major Bleeding
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of clinically relevant non-major bleeding, defined as clinically overt bleeding that does not meet the criteria for major bleeding but leads to hospitalization or an increased level of care, medical or surgical treatment, or a change in antithrombotic therapy. |
From randomization until 1 year after enrollment of the last participant
|
|
Clinically Relevant Bleeding
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of clinically relevant bleeding, defined as a composite of major bleeding or clinically relevant non-major bleeding. |
From randomization until 1 year after enrollment of the last participant
|
|
Broad Net Adverse Clinical Events
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Time to the first occurrence of a broad net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, major bleeding, or clinically relevant non-major bleeding. |
From randomization until 1 year after enrollment of the last participant
|
|
All-cause Mortality
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Death due to any cause occurring during the study follow-up period. |
From randomization until 1 year after enrollment of the last participant
|
|
Permanent Discontinuation Due to Adverse Events
Periodo de tiempo: From randomization until 1 year after enrollment of the last participant
|
Permanent discontinuation of the assigned study drug due to any adverse event during follow-up. |
From randomization until 1 year after enrollment of the last participant
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Eun Kyoung Kim, Samsung Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2026-07-044
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data that underlie the results reported in the main publication may be shared with qualified researchers upon reasonable request.
Marco de tiempo para compartir IPD
Beginning after publication of the main study results; no predetermined end date.
Criterios de acceso compartido de IPD
Data may be made available to qualified researchers upon reasonable request for scientifically appropriate research purposes. Requests will be reviewed by the principal investigator and the study steering committee based on the scientific merit and appropriateness of the proposed research and data-use plan. Data sharing will be conducted in accordance with applicable regulations and participant privacy requirements.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .